US-based advanced ophthalmic technologies provider Intalight has secured the CE mark for its DREAM OCT platform and plans to commercialise in the European Union (EU).
DREAM OCT (Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities) is the latest advancement in Optical Coherence Tomography (OCT) technology.
The CE mark approval highlights the DREAM OCT’s ability to deliver high-quality OCT images, featuring an ultrawide field single scan that provides a 130° OCTA image.
Its swept-source 12 mm super-depth scanning offers superior imaging of the choroid, retina, and a significant portion of the vitreous space.
The advanced anterior scanning capabilities achieve 16.2 mm (in air), allowing comprehensive imaging from the cornea to the anterior vitreous in one scan.
Intalight CEO and co-founder Bing Li said: “Over the past few years, we’ve heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth.
“DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP’s know.”
Intalight operates sites in Luoyang, Shanghai, and Silicon Valley, focusing on developing advanced ophthalmic technologies.
The company collaborates with leading retina academic institutions and private practices in Asia, Europe, and the US.
DREAM OCT’s ultra-wide swept-source technology caters to the needs of retina specialists and ophthalmologists, delivering detailed imaging for enhanced patient care.
Over 160 peer-reviewed papers have utilised findings from DREAM OCT devices.
Also, the device has become essential for ophthalmologists in clinical practice and research.
Intalight chief commercial officer Joe Garibaldi said: “This is such exciting news for Intalight that there’s no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US.
“We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval.”
Intalight chairman and founder Shawn Peng said: “Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT.
“This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.”
